Collaborations

Current Agreements

Orion has entered into numerous license agreements and collaborations with academic institutions and universities worldwide. These collaborations have allowed Orion to strengthen its biomarker discovery and product pipeline. A summary of each commercial agreement is shown here:

Collaboration and Commercial Agreements
Institution	Principal Investigator	Description of Collaboration
Johns Hopkins University School of Medicine Baltimore, MD	Andrew P. Feinberg, M.D., M.P.H.	Use Orion's methylation technologies to identify biomarkers correlating with colon cancer and psychiatric disorders
University of Glasgow Scotland, UK	Robert Brown, Ph.D.	Use Orion's methylation technologies to identify biomarkers useful in the detection and treatment of lung, breast, and ovarian cancer
Mayo Clinic Rochester, MN	Stephen N. Thibodeau, Ph.D	Study the clinical utility of Orion's proprietary biomarkers in more than a dozen cancer types

Future Agreements

To maximize the value of the methylation detection and discovery patent estate, Orion is exploring opportunities to further capitalize on the power of the MethylScope and MethylScreen estates in the research use market. Discussions regarding potential acquisitions and/or licenses to the estates for research use only are currently underway with various entities.